supported by the National Natural Science Foundation of China(82072675,82273197,82173933);Fundamental Research Funds for the Central Universities(020814380160).
Background:As a novel blocker of vascular endothelial growth factor receptor(VEGFR),fruquintinib has been approved for treating colorectal cancer(CRC).However,its dosage and therapeutic efficacy are limited by its wid...
2024年2月26日,赣南医科大学心脑血管疾病防治教育部重点实验室张书永教授团队联合王烈峰教授、曾祥福教授等多个课题组在国际权威期刊Journal of Experimental&Clinical Cancer Research(IF=11.3)上发表题为《Combined inhibition of H...
supported by grants from the Natural Science Foundation of China for Innovation Research Group(81821005);the National Natural Science Foundation of China(82273948 and 81573271);the"Personalized Medicines,Molecular Signaturebased Drug Discovery and Development",Strategic Priority Research Program of the Chinese Academy of Sciences(XDA12020203 and XDA12020228,China);the National Science&Technology Major Project"Key New Drug Creation and Manufacturing Program",China(2018ZX09711002-011-016);the Youth Innovation Promotion Association of CAS(2018324,China).
Glioblastoma(GBM)is the most common and aggressive malignant brain tumor in adults and is poorly controlled.Previous studies have shown that both macrophages and angiogenesis play significant roles in GBM progression,...